The primary objective of this project is to assess “real-world” antithrombotic management for secondary stroke prevention in patients with atrial fibrillation and a recent diagnosis of stroke or TIA, and to monitor the anticipated practice changes following Health Canada approval of dabigatran and other novel anticoagulants over the next 2 years.